247 related articles for article (PubMed ID: 37626854)
1. Coming of Age: Targeting Cyclin K in Cancers.
Xiao Y; Dong J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626854
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
5. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
[TBL] [Abstract][Full Text] [Related]
6. New functional activities for the p21 family of CDK inhibitors.
LaBaer J; Garrett MD; Stevenson LF; Slingerland JM; Sandhu C; Chou HS; Fattaey A; Harlow E
Genes Dev; 1997 Apr; 11(7):847-62. PubMed ID: 9106657
[TBL] [Abstract][Full Text] [Related]
7. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
Lee YM; Sicinski P
Cell Cycle; 2006 Sep; 5(18):2110-4. PubMed ID: 16969111
[TBL] [Abstract][Full Text] [Related]
8. Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.
Zabihi M; Lotfi R; Yousefi AM; Bashash D
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1585-1606. PubMed ID: 35781526
[TBL] [Abstract][Full Text] [Related]
9. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Santamaria D; Ortega S
Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
12. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
13. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future.
M Manohar S
Future Med Chem; 2022 Jul; 14(14):1087-1105. PubMed ID: 35703127
[TBL] [Abstract][Full Text] [Related]
16. Less-well known functions of cyclin/CDK complexes.
Palmer N; Kaldis P
Semin Cell Dev Biol; 2020 Nov; 107():54-62. PubMed ID: 32386818
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer--a review.
Sarita Rajender P; Ramasree D; Bhargavi K; Vasavi M; Uma V
J Recept Signal Transduct Res; 2010 Aug; 30(4):206-13. PubMed ID: 20560705
[TBL] [Abstract][Full Text] [Related]
18. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Shan W; Yuan J; Hu Z; Jiang J; Wang Y; Loo N; Fan L; Tang Z; Zhang T; Xu M; Pan Y; Lu J; Long M; Tanyi JL; Montone KT; Fan Y; Hu X; Zhang Y; Zhang L
Cell Rep; 2020 Jul; 32(2):107884. PubMed ID: 32668240
[TBL] [Abstract][Full Text] [Related]
19. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction.
Chiu HC; Huang WR; Liao TL; Chi PI; Nielsen BL; Liu JH; Liu HJ
J Biol Chem; 2018 Aug; 293(32):12542-12562. PubMed ID: 29907572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
